Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label romiplostim in ITP (extension of prior AMG 531 ITP studies)
2004-000172-13Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP) and Thrombocytopenia, sponsored by Amgen. Primary endpoint: Incidence of adverse events. Started Feb 2005; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)Thrombocytopenia
Beyond the preview
Go deeper on 2004-000172-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000172-13.